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The paper by Twardowschy et al.1 is 
certainly opportune since phenytoin is 
considered extremely effective as a drug 
treatment for focal seizures and focal ep-
ilepsy syndromes2 and it is still one of the 
most used antiepileptic drugs worldwide, 
including in the USA3. Experts in the field 
of epilepsy have a tendency to reduce the 
use of phenytoin mainly due to its adverse 
effects and because it is a potent inducer of 
the hepatic microsomal system which may 
lead to serious potential drug interactions. 
The word pharmacogenetics was first 
introduced in the late 1950s4 and today is 
used to indicate the existence of DNA se-
quence variations that may impact the way 
the body responds to drugs. Overall these 
DNA variations can occur in genes coding 
for [i] drug transporters, [ii] enzymes in-
volved in drug metabolism or [iii] in pro-
teins related to drug targets5. Over the 
past decade there has been a greater un-
derstanding on how changes in DNA se-
quence may lead to changes in protein 
function. This was achieved mainly by the 
advances in our understanding of the hu-
man genome, starting with the comple-
tion of the Human Genome Project6 and 
the subsequent studies7. However, it re-
mains a major challenge to effectively ap-
ply this knowledge into the daily clinical 
practice. Recently, regulatory agencies ap-
proved the clinical use of some pharma-
cogenetic tests8; however, the promise of 
‘personalized medicine’ is still a futuristic 
vision and for the most skeptical an unat-
tainable reality9. In the specific case of an-
tiepileptic drugs a serious allergic cutane-
ous reactions caused by CBZ therapy was 
found to be significantly more common 
in patients with a particular human leu-
kocyte antigen (HLA) allele: HLA-B* 1502. 
This allele occurs almost exclusively in pa-
tients with Asian ancestry. A recent FDA 
alert recommends that patients withances-
try of an at-risk population be screened for 
the HLA-B* 1502 allele prior to starting 
CBZ and that positive patients not be ex-
posed to it10. Controversy aside, the fact 
of the matter is that experience has taught 
us that one should never underestimate 
the complexity of human biology, and this 
is certainly true for the genetic influenc-
es on proteins regulating pharmacokinet-
ic and pharmacodynamic processes which 
are far from being fully understood. Until 
then we will have an incomplete view, and 
therefore subject to error. At this point a 
more broadly application of pharmacoge-
netics to clinical practice is still a promise; 
however, the field offers already opportu-
nity for a very interesting area of scientific 
investigation as well illustrated by the pa-
per by Twardowschy et al.1.
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